Comparative analysis of human cytomegalovirus-specific CD4+ T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Evaluation of human cytomegalovirus (HCMV)-specific T-helper immunity could contribute in optimizing anti-HCMV therapy in human immunodeficiency virus (HIV)-infected patients. Testin the lymphoproliferative response (LPR) is the standard technique used to evaluate T-helper response, but its use in the routine diagnostic laboratory setting can be problematic. The most promising new alternative technique is the determination of HCMV-specific CD4+ T-cell frequency by flow cytometry detection of intracellular cytokine production after short-term antigen-specific activation of peripheral blood mononuclear cells. HCMV-specific LPR and CD4+ T-cell frequency were compared in a group of 78 blood samples from 65 HIV-infected patients. The results showed concordance in 80.7% of samples. In addition, comparative analysis of sequential blood samples from 13 HIV-infected patients showed that while in about half of patients the T-helper HCMV-specific immune response remained stable during highly active antiretroviral therapy (HAART), in the other half declining levels of the HCMV-specific CD4+-mediated immune response were determined by either one or both assays. In conclusion, our data suggest that the determination of HCMV-specific CD4+ T-cell frequency can be considered a valuable alternative to the LPR test for the detection of HCMV-specific T-helper response in HIV-infected patients. It could facilitate wider screening of anti-HCMV T-helper activity in HIV-infected patients, with potential benefits for clinicians in deciding strategies of discontinuation or maintenance of anti-HCMV therapy.

Original languageEnglish
Pages (from-to)1225-1230
Number of pages6
JournalClinical and Diagnostic Laboratory Immunology
Volume8
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

T-cells
Cytomegalovirus
Viruses
HIV
T-Lymphocytes
Blood
Flow cytometry
Assays
Screening
Chemical activation
Cytokines
Antigens
Highly Active Antiretroviral Therapy
Blood Group Antigens
Immunity
Blood Cells
Flow Cytometry
Maintenance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

@article{8713f20a60bb40558490f8c06b320c16,
title = "Comparative analysis of human cytomegalovirus-specific CD4+ T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients",
abstract = "Evaluation of human cytomegalovirus (HCMV)-specific T-helper immunity could contribute in optimizing anti-HCMV therapy in human immunodeficiency virus (HIV)-infected patients. Testin the lymphoproliferative response (LPR) is the standard technique used to evaluate T-helper response, but its use in the routine diagnostic laboratory setting can be problematic. The most promising new alternative technique is the determination of HCMV-specific CD4+ T-cell frequency by flow cytometry detection of intracellular cytokine production after short-term antigen-specific activation of peripheral blood mononuclear cells. HCMV-specific LPR and CD4+ T-cell frequency were compared in a group of 78 blood samples from 65 HIV-infected patients. The results showed concordance in 80.7{\%} of samples. In addition, comparative analysis of sequential blood samples from 13 HIV-infected patients showed that while in about half of patients the T-helper HCMV-specific immune response remained stable during highly active antiretroviral therapy (HAART), in the other half declining levels of the HCMV-specific CD4+-mediated immune response were determined by either one or both assays. In conclusion, our data suggest that the determination of HCMV-specific CD4+ T-cell frequency can be considered a valuable alternative to the LPR test for the detection of HCMV-specific T-helper response in HIV-infected patients. It could facilitate wider screening of anti-HCMV T-helper activity in HIV-infected patients, with potential benefits for clinicians in deciding strategies of discontinuation or maintenance of anti-HCMV therapy.",
author = "G. Piccinini and G. Comolli and E. Genini and D. Lilleri and R. Gulminetti and R. Maccario and Revello, {M. G.} and G. Gerna",
year = "2001",
doi = "10.1128/CDLI.8.6.1225-1230.2001",
language = "English",
volume = "8",
pages = "1225--1230",
journal = "Clinical and Diagnostic Laboratory Immunology",
issn = "1071-412X",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Comparative analysis of human cytomegalovirus-specific CD4+ T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients

AU - Piccinini, G.

AU - Comolli, G.

AU - Genini, E.

AU - Lilleri, D.

AU - Gulminetti, R.

AU - Maccario, R.

AU - Revello, M. G.

AU - Gerna, G.

PY - 2001

Y1 - 2001

N2 - Evaluation of human cytomegalovirus (HCMV)-specific T-helper immunity could contribute in optimizing anti-HCMV therapy in human immunodeficiency virus (HIV)-infected patients. Testin the lymphoproliferative response (LPR) is the standard technique used to evaluate T-helper response, but its use in the routine diagnostic laboratory setting can be problematic. The most promising new alternative technique is the determination of HCMV-specific CD4+ T-cell frequency by flow cytometry detection of intracellular cytokine production after short-term antigen-specific activation of peripheral blood mononuclear cells. HCMV-specific LPR and CD4+ T-cell frequency were compared in a group of 78 blood samples from 65 HIV-infected patients. The results showed concordance in 80.7% of samples. In addition, comparative analysis of sequential blood samples from 13 HIV-infected patients showed that while in about half of patients the T-helper HCMV-specific immune response remained stable during highly active antiretroviral therapy (HAART), in the other half declining levels of the HCMV-specific CD4+-mediated immune response were determined by either one or both assays. In conclusion, our data suggest that the determination of HCMV-specific CD4+ T-cell frequency can be considered a valuable alternative to the LPR test for the detection of HCMV-specific T-helper response in HIV-infected patients. It could facilitate wider screening of anti-HCMV T-helper activity in HIV-infected patients, with potential benefits for clinicians in deciding strategies of discontinuation or maintenance of anti-HCMV therapy.

AB - Evaluation of human cytomegalovirus (HCMV)-specific T-helper immunity could contribute in optimizing anti-HCMV therapy in human immunodeficiency virus (HIV)-infected patients. Testin the lymphoproliferative response (LPR) is the standard technique used to evaluate T-helper response, but its use in the routine diagnostic laboratory setting can be problematic. The most promising new alternative technique is the determination of HCMV-specific CD4+ T-cell frequency by flow cytometry detection of intracellular cytokine production after short-term antigen-specific activation of peripheral blood mononuclear cells. HCMV-specific LPR and CD4+ T-cell frequency were compared in a group of 78 blood samples from 65 HIV-infected patients. The results showed concordance in 80.7% of samples. In addition, comparative analysis of sequential blood samples from 13 HIV-infected patients showed that while in about half of patients the T-helper HCMV-specific immune response remained stable during highly active antiretroviral therapy (HAART), in the other half declining levels of the HCMV-specific CD4+-mediated immune response were determined by either one or both assays. In conclusion, our data suggest that the determination of HCMV-specific CD4+ T-cell frequency can be considered a valuable alternative to the LPR test for the detection of HCMV-specific T-helper response in HIV-infected patients. It could facilitate wider screening of anti-HCMV T-helper activity in HIV-infected patients, with potential benefits for clinicians in deciding strategies of discontinuation or maintenance of anti-HCMV therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034760605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034760605&partnerID=8YFLogxK

U2 - 10.1128/CDLI.8.6.1225-1230.2001

DO - 10.1128/CDLI.8.6.1225-1230.2001

M3 - Article

VL - 8

SP - 1225

EP - 1230

JO - Clinical and Diagnostic Laboratory Immunology

JF - Clinical and Diagnostic Laboratory Immunology

SN - 1071-412X

IS - 6

ER -